Back to rankings
England - London • Industry focus
4

Life sciences and healthcare

Mishcon de Reya LLP logo

Mishcon de Reya LLP

More information
Mishcon de Reya LLP advises a range of pharma, medical devices, digital health and biotech clients in contentious and non-contentious matters, including fundraising, patent litigation, and strategic collaborations. IP specialist Patrick Farrant leads the team. Robert Griffiths joined from Deloitte LLP in July 2024, bringing experience in technology disputes. Gayle Curry is no longer at the firm.
Legal 500 Editorial commentary

Testimonials

Collated independently by Legal 500 research team.

  • ‘We were provided with an extremely high quality of service backed by a wealth of knowledge in the area. They gained our trust immediately - absolutely crucial when dealing with high stress, high pressure, high-risk legal situations. They excelled at understanding our case and how they could help us, and provided us with a roadmap out that benefitted us long term. They listened and understood where we had concerns and were patient when we didn't understand. They checked arguments with expert barristers as needed, but only when it was economically sensible. As a company, we wouldn't go elsewhere and would recommend the team wholeheartedly.’

  • ‘Our case was dealt with by Campbell Forsyth and James Holland at Mishcon de Reya. Campbell has an almost unrivalled knowledge of the field and we felt instantly at ease with him representing us. Talking through situations, Campbell comes up with smart strategies and ideas on the spot that are excellent arguments and also commercially beneficial. James took the bulk of our correspondence. We were extremely impressed by his maturity and ability to quickly understand our quite complex case (which had been building for years) and distill it down to a very impressive defence. Additionally, he showed us empathy and patience throughout. He took the time to explain his arguments clearly to us and was always available for a call when needed.’

Key clients

  • Relation Therapeutics
  • Dr Reddy’s Laboratories
  • Zentiva
  • Luye Pharma
  • RQ Bio
  • Ikarovec
  • DIOsynvax Ltd
  • TTP Plc
  • Vicebio Limited
  • Nucleome Therapeutics Ltd
  • Adsilico Ltd
  • Centauri Therapeutics

Work highlights

Advising Relation Therapeutics on two multi-programme strategic collaborations with GSK, in connection with the identification and validation of novel therapeutic targets for fibrotic disease and osteoarthritis.
Advising Nucleome Therapeutics, a spin out from the University of Oxford, on securing Series A funding of £18,750,000 from the venture arms of Pfizer, Johnson & Johnson and Merck alongside British Patient Capital and Oxford Science Enterprises Limited.
Advising Dr Reddy's Laboratories on its claim for compensation under cross-undertakings given by Bayer to secure short-lived interim injunctions pending the outcome of trial and appeal proceedings concerning the validity of its Rivaroxaban dosage patent.

Practice head

Patrick Farrant

Other key lawyers

Campbell Forsyth; James Holland